The PPV of PSA testing for clinically significant prostate cancer was 0.19 (0.15–0.22) for the top 20% of genetic risk (PPV80) and 0.26 (0.19–0.33) for the top 5% of genetic risk (PPV80; Fig. 1). This evidence concerns the gene KLK3 and prostate carcinoma.